Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synta Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (5)	2/8/2007 2:31:30 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 112

Well, they had a couple rounds before oral anti-il12/23 flamed out in crohns and psoriasis. From what I can tell they pulled the IPO last year at a much higher valuation thinking those results would be positive. The target es muy caliente. But the cpd flopped and probably will for RA too. So, today the price may look better but the clinical program looks really different (hsp70 in mm showed itself better than expected I suspect). Worth having a syta board at any rate.

To: rkrw who wrote (5)	8/22/2007 4:10:22 PM
From: tuck	Respond to of 112

I have been averaging down, with my latest chunk at $5.38 just now. The only red flags I can think of is that we were supposed to see a P3 trial start in the middle of the year, and that got pushed into 3rd Q. So did the 1H filing of IND for 9090. The other issue is that they will need to finance soon. Still, with no obvious clinical negatives, why would folks want to bail, particularly if they didn't get their shares as cheaply as in other IPOs? Hope I'm not setting myself up to average down even more, given the above; but these fairly minor delays don't seem to justify the beating the stock is taking, IMO. Cheers, Tuck